Quadrant Capital Group’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Quadrant Capital Group’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-119	Closed	-$2K	–	2778
2021 Q3	$2K	Sell	119 -42	-26%	-$1.16K	﹤0.01%	2226
2021 Q2	$6K	Buy	161 +21	+15%	+$644	﹤0.01%	1809
2021 Q1	$4K	Buy	140 +27	+24%	+$690	﹤0.01%	1916
2020 Q4	$2K	Buy	+113	New	+$2.49K	﹤0.01%	2030

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Quadrant Capital Group's DRNA Position: Q4 2021 in Review

Quadrant Capital Group sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 119 shares — an estimated $2K sold.

Quadrant Capital Group first reported a position in DRNA in Q4 2020 and held it in 4 quarters. The position peaked at $6K in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Quadrant Capital Group reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Quadrant Capital Group sold 119 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $2K.
Quadrant Capital Group first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2020 and held it in 4 quarters.
Quadrant Capital Group's Dicerna Pharmaceuticals, Inc. position peaked at $6K in Q2 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Quadrant Capital Group's 13F filing for Q4 2021, filed 1 Feb 2022.